Browse by author
Lookup NU author(s): Professor Moein MoghimiORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
A wide variety of nanocarriers and particularly cancer nanomedicines activate the complement system, which is the first line of the innate immune defence mechanism. Complement activation may induce inflammatory responses, but such responses arising from uncontrolled complement activation could be life threatening. Accordingly, the role of complement in initiation of adverse reactions to particulate and polymer therapeutics is receiving increasing attention. Furthermore, the involvement of complement-activation products in promoting tumour growth has also been indicated. This could be of serious concern for development of cancer nanomedicines and cancer nanotechnology initiatives. These concepts are reviewed with preliminary evidence that intra-tumoural accumulation of model long circulating nanoparticles could promote tumour growth. © 2014 Elsevier B.V. All rights reserved.
Author(s): Moghimi SM
Publication type: Article
Publication status: Published
Journal: Journal of Controlled Release
Print publication date: 28/09/2014
Online publication date: 16/04/2014
Acceptance date: 29/03/2014
ISSN (print): 0168-3659
ISSN (electronic): 1873-4995
PubMed id: 24746624
Altmetrics provided by Altmetric